Drug Trial Radar · NCT05547100
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Sep 14, 2022
Primary completion
Nov 19, 2022
Study completion Nov 19, 2022
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical lactation study is to provide information regarding the PK and amount of OLZ/SAM in breast milk and estimated infant exposure.
Conditions
- Focus of Study is on Healthy Lactating Women
Interventions
LYBALVIDrug
5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve from time zero to 48 hours post-dose (AUC0 48)Time frame: Up to 15 days
- Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)Time frame: Up to 15 days
- Area under the concentration-time curve from time zero to infinity (AUC∞)Time frame: Up to 15 days
- \Maximum observed concentration (Cmax)Time frame: Up to 15 days
- Time to reach Cmax (tmax)Time frame: Up to 15 days
- Terminal half-life (t½)Time frame: Up to 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alkermes Investigator Site
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.